Pancreatic Cancer Research

ResearcherUniversitätsmedizin GreifswaldNo recent work listed

André Käding

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1989-8784; OpenAlex author ID A5079362864. Sources: OpenAlex.

Their work

Papers
11 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper

Papers 11

  1. Murine Macrophages Modulate Their Inflammatory Profile in Response to Gas Plasma-Inactivated Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers13112525↗
  2. RAW 264.7 Macrophage Polarization by Pancreatic Cancer Cells - A Model for Studying Tumour-promoting Macrophages. First author DOI 10.21873/anticanres.13416↗
  3. Risk Assessment of kINPen Plasma Treatment of Four Human Pancreatic Cancer Cell Lines with Respect to Metastasis. Last author DOI 10.3390/cancers11091237↗
  4. Cold Physical Plasma-Treated Buffered Saline Solution as Effective Agent Against Pancreatic Cancer Cells. First author DOI 10.2174/1871520618666180507130243↗
  5. Non-thermal plasma-treated solution demonstrates antitumor activity against pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1038/s41598-017-08560-3↗
  6. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. First author DOI 10.18632/oncotarget.15019↗
  7. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Co-author DOI 10.1016/j.pan.2016.03.005↗
  8. TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response. Co-author DOI 10.1097/mpa.0000000000000469↗
  9. Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.06.010↗
  10. A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines. Co-author DOI 10.1159/000329413↗
  11. In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. First author DOI 10.1186/1471-2407-11-40↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sander Bekeschus · 5 shared papers, 2017–2021 · strength 0.48
  2. Lars-Ivo Partecke · 5 shared papers, 2013–2021 · strength 0.44
  3. Kim Rouven Liedtke · 4 shared papers, 2017–2021 · strength 0.40
  4. Wolfram von Bernstorff · 7 shared papers, 2011–2017 · strength 0.32
  5. Lars Ivo Partecke · 5 shared papers, 2011–2017 · strength 0.27
  6. Aydar Khabipov · 2 shared papers, 2019–2021 · strength 0.25
  7. Frank Ulrich Weiß · 5 shared papers, 2011–2017 · strength 0.18
  8. Katharina Beyer · 3 shared papers, 2016–2017 · strength 0.17
  9. Julia V. Mayerle · 4 shared papers, 2011–2017 · strength 0.15
  10. Stephan Kersting · 1 shared paper, 2021 · strength 0.13
  11. Wolfram Keßler · 2 shared papers, 2016–2017 · strength 0.11
  12. Markus M. Lerch · 3 shared papers, 2011–2016 · strength 0.09
  13. Angela Privat‐Maldonado · 1 shared paper, 2019 · strength 0.08
  14. Annemie Bogaerts · 1 shared paper, 2019 · strength 0.08
  15. Pia Menges · 1 shared paper, 2016 · strength 0.05
  16. A. Stier · 1 shared paper, 2011 · strength 0.02
  17. Ivo L Partecke · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.